Home
Search

Press Releases

Get the latest on BIO's announcements, positions and views on everything from healthcare to biofuels. 

Featured Press Releases
BIO Statement on December 2025 ACIP Meeting
WASHINGTON, D.C. – Phyllis Arthur, Executive Vice President and Head of Health Policy and Programs of the Biotechnology Innovation Organization (BIO) released the following statement on the December 2025 ACIP meeting.“For decades, the CDC’s Advisory…
Learn more
BIO Statement on the Retirement of Richard Pazdur…
WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on reports of the retirement of Richard Pazdur from the US FDA.“Dr. Pazdur has dedicated decades of his career…
Learn more
BIO Statement on House Passage of Mikaela Naylon…
WASHINGTON, D.C. – The Biotechnology Innovation Organization (BIO) released the following statement on today’s passage of the Mikaela Naylon Give Kids a Chance Act in the House of Representatives.“The unanimous House passage of the Mikaela Naylon…
Learn more
All Press Releases
  • Show All
Search
Results
Event Tags
Trump Administration Move to Issue RFS Waivers "Beyond Egregious"
January 12, 2021
Stephanie Batchelor, vice president of BIO's Industrial and Environmental Section, released the following statement in reaction to the Trump administration's move to issue Renewable Fuel Standard (RFS) waivers for the 2019 compliance year. “This…
BIO Releases Statement Concerning Future Political Giving
January 11, 2021
Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), released the following statement on BIO's political contributions:   "As of today BIO will be pausing our political giving so we can…
BIO Statement on CMS' Approval of TennCare Medicaid Waiver
January 11, 2021
Dan Durham, Executive Vice President for Health Policy at the Biotechnology Innovation Organization, released the following statement regarding the recent decision by the Centers for Medicare and Medicaid Services (CMS) to approve the Tennessee…
BIO's Dr. Michelle McMurry-Heath Responds to "Unconscionable" Attacks on U.S. Capitol
January 6, 2021
Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization, made the following comments in response to today's violence at the United States Capitol: "Today we watched in horror as angry and unruly mobs attacked…
Injunction Placed on Punitive and Political Maneuver by Administration
December 29, 2020
A judge in the United States District Court for the Northern District of California yesterday issued a preliminary injunction blocking the Administration’s “Most Favored Nation” reimbursement policy for certain drugs administered by Medicare Part B…
Modernizing Oversight of Animal Biotechnology Will Help Tackle Climate Change and Nutrition Challenges
December 21, 2020
The Biotechnology Innovation Organization (BIO) appreciates the U.S. Department of Agriculture’s (USDA) longstanding commitment to food and agricultural innovation and looks forward to reviewing the Advanced Notice of Proposed Rulemaking (ANPR)…
New Website Will Combat Vaccine Myths, Boost Public Confidence, Increase Acceptance
December 4, 2020
Public opinion polls show there is significant mistrust among the American public in the safety and efficacy of vaccines. So today, the Biotechnology Innovation Organization (BIO) announced the launch of COVIDVaccineFacts.org. As a subsidiary…
BIO Leads Group Challenging Administration’s “Most Favored Nation” Rule
December 4, 2020
The Biotechnology Innovation Organization (BIO), the California Life Sciences Association (CLSA), and BIOCOM California today filed a challenge against the Department of Health and Human Services’ (HHS) attempt, during the final days of the Trump…
BIO's Dr. McMurry-Heath Applauds Nasdaq's Proposal on Mandatory Diversity for Listed Companies
December 2, 2020
Washington, DC (December 2, 2020) - Dr. Michelle McMurry-Heath, President and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement regarding Nasdaq's filing with the Securities and Exchange Commission…
BIO’s Dr. McMurry-Heath Calls Foreign Price Controls a “Fatally Flawed Regulation” That Will “Endanger Our Most Vulnerable Americans”
November 20, 2020
Washington, DC (November 20, 2020) – Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), issued the following statement after the Trump administration moved forward with its threat to impose…
gooddaybio-cover-final
Daily News You Can’t Afford to Miss

Read it in under 3 minutes!

The Good Day BIO newsletter is the only daily newsletter at the intersection of biotech, politics, and policy. 

Sign Up Today